Platinum Discovery successfully completes contract to discover new targets for cancer immunotherapeutics

Platinum Discovery has successfully completed a major contract to discover tumour-specific targets for a new generation of anti-cancer therapies. In collaboration with the University of Dundee and Tayside Clinical Trials Unit (TCTU) at Tayside Medical Science Centre, based at Ninewells Hospital, Dundee, Platinum Discovery led the collaboration with Epitopea, a trans-Atlantic cancer immunotherapeutic company. Platinum Discovery successfully screened for targets uniquely found on the surface of tumour tissue. The client now plans to develop immunotherapeutics targeting these novel targets using a range of modalities.

Revolutionising cancer treatment through neoantigen discovery

At Platinum Discovery, we are driven by a singular mission: to advance cancer immunotherapy through the identification and discovery of tumour-specific neoantigens. These neoantigens are the cornerstone for creating precise, targeted cancer vaccines that have the potential to transform how we treat and prevent cancer. Our proprietary technology, privileged access to state-of-the-art mass spectrometry facilities […]